VPC-18005

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA.

VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA.(In Vitro):VPC-18005 (1 and 10 μM) produced a 20–30% decrease in the dissemination of cancer cells in zebrafsh. VPC-18005 (5 μM) inhibits pETS-luc reporter activity with IC50s of 3 and 6 μM in PNT1B-ERG and VCaP cells, respectively. VPC-18005 antagonizes the metastatic potential of ERG-expressing prostate cells and suppresses ERG reporter activity without exhibiting overt cytotoxicity. VPC-18005 inhibits migration and invasion of ERG-overexpressing cells in vitro.

——

Others

Other Targets

——

——

——

2242480-48-2

319.4

C15H17N3O3S

>98% (HPLC)

——

N(/N=C\C1=CC=C(C(C)C)C=C1)=C\2/SC(CC(O)=O)C(=O)N2

——

(-20℃)

With Ice Pack

≥ 2 years